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Abstract To examine the association between body mass
index (BMI), use of menopausal hormone therapy (HT),
and incidence of uterine fibroids in postmenopausal
women, 610,604 postmenopausal women without prior
hysterectomy or diagnosis of fibroids were followed as part
of a large United Kingdom prospective cohort study. We
used Cox regression models to calculate adjusted relative
risks (RRs) of surgically-confirmed fibroids (defined as a
hospital admission with uterine fibroids as a primary di-
agnosis with a related surgical procedure), in relation to
BMI and use of HT. During an average of 11.4 years of
follow-up, 3561 women were admitted to hospital with
surgically-confirmed fibroids. Five-year incidence rates
decreased with age, from 0.50 % (1 in 200 women) at age
50–54, to 0.11 % (1 in 1000 women) at age 75–79. The
5-year rate in postmenopausal women aged 50–54 was
about a quarter that seen in premenopausal women of the
same age (1 in 200 vs. 1 in 50). Compared with normal
weight women, obese women had a RR of surgically-de-
tected fibroids of 1.46 (95 % CI 1.33–1.59; p\ 0.0001).
HT use was associated with a RR of 2.33 (95 % CI
2.18–2.49; p\ 0.0001) in ever versus never users. When
we analysed HT use and BMI together, obese vs. normal
weight never users had a RR of 2.00 (95 % CI 1.77–2.26):
the highest risks were seen in women who were obese and
had ever used HT, RR = 3.30 (95 % CI 2.88–3.79).
Uterine fibroids continue to occur in postmenopausal
women; obesity and hormone therapy use are important
modifiable risk factors.
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Introduction
Uterine fibroids are benign monoclonal smooth muscle
tumours of the uterus [1], and are the most common pelvic
tumour in women [2]. Asymptomatic in at least 50 % of
cases [3], fibroids are nonetheless an important cause of
morbidity and a common reason for surgery. A recent study
estimated the annual cost of treating uterine fibroids in the
United States at $34.4 billion dollars [4].
Prevalence rates ranging from 5 to 77 % [5] have been
reported, reflecting differences in case definition and
population studied. The highest estimates come from
pathologic examination of hysterectomy specimens [6].
Fibroids are an indication for a large proportion of hys-
terectomies [7]; estimates based on pathological findings
are likely to overestimate prevalence, and may preferen-
tially identify women with specific symptoms, such as pain
or bleeding [8]. Reported risk factors for uterine fibroids
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include black ethnicity, family history, parity, and obesity
[1, 2, 9–11].
Factors that increase exposure to oestrogen appear to
increase the incidence of uterine fibroids [10]. Fibroids are
not seen before puberty, occur most commonly in women
of reproductive age, and are commonly said to regress after
the menopause [12]. The reduction in size or resolution of
fibroids in postmenopausal women [10–12] is thought to be
due to the lower average levels of endogenous ovarian
hormones after the menopause. However, in post-
menopausal women average oestrogen levels have been
found to increase with increasing body mass index (BMI)
[13]. Use of exogenous hormones in the form of meno-
pausal hormone therapy (HT) might also be expected to
increase risk, although evidence for this has been relatively
scarce [12].
The Million Women Study provides a unique opportu-
nity to examine the relationship between adiposity, HT use
and the incidence of uterine fibroids in postmenopausal
women. This prospective cohort study collected detailed
information at recruitment on participants’ menopausal
status, use of HT, and height and weight. There is virtually
complete follow-up for cause-specific hospital admissions,
incident cancers and death.
In order to clarify the public health impact of fibroids in
postmenopausal women, we used a strict case definition,
including only clinically relevant disease involving surgi-
cal detection and/or treatment. We aimed to determine
whether postmenopausal women who were overweight or
obese were more likely to have surgically-confirmed fi-
broids than normal weight women. We also investigated
whether women who had ever used HT were at an in-
creased risk of fibroids, and whether the use of HT mod-
ified the association with BMI.
We have used the term ‘incidence rate’ throughout the
study, however surgically-confirmed fibroids in post-
menopausal women represent a subset of true incidence;
cases in our analysis are those in which uterine fibroids, or
a co-morbid condition, have resulted in a surgical diagnosis
of fibroids.
Materials and methods
The Million Women Study is a large prospective cohort
study which recruited 1.3 million women, most aged
50–64 years, between 1996 and 2001 via the National
Health Service (NHS) Breast Screening Programme. Full
details of the study design and methods are described
elsewhere [14]. Approximately one in two women in this
age range in the recruitment areas agreed to participate in
the study, or around one in four women in this age range in
the entire United Kingdom. Participants gave written
informed consent for use of their questionnaire data for
research, and for ongoing linkage to nationally held reg-
istry and health data. The study has Multi-Centre Research
Ethics Committee approval (MREC 97/01).
Information about personal characteristics including
height and weight, reproductive history, medical history,
family history, menopausal status, and HT use was col-
lected at baseline. The recruitment and follow-up ques-
tionnaires can be viewed at www.millionwomenstudy.org.
Postmenopausal women were defined as those who re-
ported having undergone a natural menopause or having
had a bilateral oophorectomy prior to recruitment. Body
mass index (kg/m2) was calculated from self-reported
weight and height at recruitment. This has been shown in
Million Women Study participants to correlate closely with
values based on measured variables [15]. Standard World
Health Organization definitions [16] were used to cate-
gorise women with a BMI of \25 kg/m2 as ‘normal’,
25–29.9 kg/m2 as ‘overweight’, and 30 kg/m2 or more as
‘obese’. HT use was self-reported by participants at base-
line. Reliability of reporting has been checked on a subset
of participants and found to be excellent when compared
with general practice prescription records [17].
All study participants are flagged on the NHS Central
Registers, so that cancer registrations and deaths are rou-
tinely notified to study investigators. In addition, par-
ticipants are linked using their name, date of birth, and
NHS number (a unique personal identifier on all NHS
health records) to NHS hospital admission databases,
Hospital Episode Statistics (HES) in England and the
Scottish Morbidity Records (SMR) in Scotland [18, 19].
The hospital records include day case and overnight stays
to all NHS hospitals from April 1997 to March 31, 2011
(England); and from January 1981 to December 31, 2008
(Scotland). For each hospital admission, diagnoses are
coded according to the International Classification of Dis-
eases 10th revision (ICD-10) [20] and procedures coded
according to the Office of Population Censuses Classifi-
cation of Surgical Operations and Procedures (OPCS-4)
[21].
The outcome of interest (‘surgically-confirmed fibroids’)
is defined as a first hospital admission (including day-case
admissions) after recruitment into the study with a primary
diagnosis of uterine fibroids (ICD-10 D25) together with a
related surgical procedure during the admission, limited to
one (or more) of the following: dilation of cervix uteri and
curettage of uterus (‘D&C’, OPCS-4 code Q10); diagnostic
endoscopic examination of uterus (Q18); abdominal hys-
terectomy (Q074); vaginal hysterectomy (Q089); endo-
scopic resection of lesion of uterus (Q171); open
myomectomy (Q092); open excision of lesion of uterus
(Q093); vaginal excision of lesion of uterus (Q161); or
diagnostic laparoscopy (T43).
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Women who reported a natural menopause or bilateral
oophorectomy at recruitment were included in the main
analysis. Exclusion criteria included self-reported hys-
terectomy at baseline, hospital diagnosis of fibroids or
record of hysterectomy prior to recruitment. Pre- or peri-
menopausal women, those with indeterminate menopausal
status, and those who began using HT prior to menopause
were also excluded, as were those with missing information
on height, weight, HT use or recruitment date.
We conducted an additional analysis looking at rates of
surgically-confirmed fibroids in women who reported being
pre-menopausal or peri-menopausal at recruitment, in order
to compare them with postmenopausal women of the same
age (50–54). These results are presented separately.
Statistical analysis
Each participant contributed person-years to the analysis
from the date of recruitment until the first identified end-
point: date of hospital admission with surgically-confirmed
fibroids, hysterectomy, date of death, emigration, or the
end of the follow-up period. For women recruited in
England follow-up was to 31 March 2011, and for women
in Scotland to 31 December 2008. For the small proportion
of women (5 %) recruited in England before 1 April 1997,
person-years were calculated from this date. Earlier HES
data, which was available in England from 1989, does not
carry the individual’s NHS number thus we were only able
to link to records from 1997 onwards.
Multivariate Cox regression models, with attained age
as the underlying time variable, were used to estimate the
relative risk of surgically-confirmed fibroids associated
with BMI and HT use. Analyses were stratified for re-
cruitment region (10 geographic regions corresponding to
the areas covered by the cancer registries), and adjusted for
deprivation using Townsend Deprivation Index quintiles
[7], smoking (never, past, current), oral contraceptive use
(never/ever), parity (0/1/2/3?), BMI (\25, 25–29, 30?),
and HT use (never vs. ever). Missing values were included
in the analysis as a separate category for each adjustment
variable. Analyses were performed using Stata version 13
(Statacorp, 2013).
Results
610,604 participants in the Million Women Study were
postmenopausal, had not had a prior hysterectomy or
recorded diagnosis of fibroids at recruitment, and provided
information on their height, weight and HT use. 34 % were
ever users of menopausal hormone therapy at baseline.
47 % were of normal weight, 36 % were overweight and
17 % were obese. Obese women were less likely to smoke,
use HT, take regular vigorous exercise, or to come from the
highest socioeconomic groups (Table 1).
During 7 million person-years of follow-up, on average
11.4 years per woman, 3561 postmenopausal participants
were admitted to hospital with a primary diagnosis of fi-
broids and a related surgical intervention.
Overall, the 5-year incidence rate of surgically-con-
firmed fibroids in the cohort was 0.3 %, or around 1 in 300
participants. This rate fell with age (Fig. 1), from 0.50
admissions per 100 women (0.50 %, 95 % CI 0.45–0.0.55)
at ages 50–54, to 0.11 (95 % CI 0.08–0.15) in women aged
75–79. Women who reported never using HT had 5-year
incidence rates which increased from 0.1 % (around 1 in
1000) in normal weight women to 0.3 % (1 in 300) in
obese women, a three-fold increase (Fig. 2). Higher rates
were seen in all BMI groups in women who reported ever
using HT, giving an overall rate of 0.4 %, (or 1 in 250)
over 5 years, with a smaller increase in rate with increasing
adiposity compared with that seen in never users of HT.
At age 50–54, premenopausal women had a 5-year in-
cidence rate of surgically-confirmed fibroids of 1.94 %
(95 % CI 1.85–2.02), which was about four times that seen
in postmenopausal women of the same age (0.50 %, 95 %
CI 0.45–0.55).
Just over half (n = 1810, 51 %) of the women with
surgically-confirmed fibroids had an abdominal or vaginal
hysterectomy during their admission. A small number had
another open procedure: myomectomy/excision of uterine
lesion (n = 30, 1 %), and 7 % had a diagnostic la-
paroscopy (n = 244). The remainder had less extensive
procedures, most commonly hysteroscopy, dilatation and
curettage, or vaginal or endoscopic resection of uterine
lesion.
Ever-use of HT increased the risk of surgically-con-
firmed uterine fibroids (Table 2). Among women who re-
ported ever using menopausal hormone therapy, the
relative risk was 2.33 (95 % CI 2.18–2.49), compared with
never users, adjusted for smoking, oral contraceptive use,
parity and deprivation.
Body mass index also had a significant impact on risk
(Table 3). Compared with women of normal weight, those
who were overweight (BMI 25–29.9) had a RR of 1.15
(95 % CI 1.07–1.24), and those who were obese (BMI
30?) a RR of 1.46 (95 % CI 1.33–1.59), adjusted for
smoking, oral contraceptive use, parity and deprivation.
While both HT use and BMI significantly increased risk
of surgically-confirmed fibroids in postmenopausal women,
when we looked at the interaction between the two risk
factors, it was clear that BMI had a stronger effect in never-
users of HT than in those who reported use of HT
(Table 4). In never users of HT, there was a doubling of
risk associated with obesity, RR 2.00 (95 % CI 1.77–2.26)
compared with that seen in normal weight women. In
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women who reported ever having used HT, the absolute
risks overall were much higher, although the increase in
relative risk associated with rising BMI was smaller. The
additional increase in risk associated with adiposity was
still present, but the magnitude of this effect was smaller in
women who used HT.
The fully adjusted relative risk of fibroids in ever users
of HT of normal BMI was 2.78 (95 % CI 2.50–3.08),
which rose to 3.05 (95 % CI 2.73–3.41) in the overweight
group, and further to 3.30 (95 % CI 2.86–3.79) in women
who were obese (Table 4).
Discussion
We examined the relationship between adiposity, meno-
pausal hormone therapy and the risk of surgically-con-
firmed uterine fibroids in postmenopausal women amongst
Table 1 Participant characteristics and follow-up, by body mass index (BMI)







Number of women (%) 610,604 (100.0) 287,208 (47.0) 217,546 (35.6) 105,850 (17.3)
Mean age at recruitment (SD) 57.8 (4.7) 57.6 (4.8) 58.0 (4.6) 57.9 (4.5)
Mean age at menarche (SD) 13.1 (1.6) 13.2 (1.6) 13.0 (1.6) 12.7 (1.6)
Past use of oral contraceptive % 52.2 (316,194) 54.5 (155,394) 50.9 (109,948) 48.5 (50,852)
Mean number of full term pregnancies (SD) 2.1 (1.3) 2.0 (1.2) 2.2 (1.3) 2.3 (1.4)
Nulliparous (n %) 12.3 (75,103) 13.6 (39,107) 11.0 (23,982) 11.4 (12,014)
Current smoker (n %) 20.4 (117,234) 22.8 (61,944) 19.1 (39,012) 16.5 (16,278)
Mean alcohol intake, units/week (SD) 3.9 (5.2) 4.3 (5.4) 3.8 (5.1) 2.8 (4.6)
Ever user of HT (n %) 34.0 (207,634) 36.3 (104,338) 33.5 (72,889) 28.7 (30,407)
Lowest quintile of socioeconomic status (n %) 26.3 (121,477) 23.6 (49,064) 26.5 (44,050) 33.0 (28,363)
Vigorous physical exercise at least once a week (n %) 38.6 (227,161) 44.1 (122,443) 36.9 (77,301) 27.0 (27,417)






Woman-years (1000s) 6974 3302 2484 1188
Mean length of follow-up (SD) 11.4 (2.5) 11.5 (2.5) 11.4 (2.5) 11.2 (2.6)


























Fig. 1 Five-year incidence rates per 100 women of surgically-
































Fig. 2 Five-year incidence rates per 100 women of surgically-
confirmed fibroids by body mass index and menopausal hormone
therapy use
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participants in a large UK prospective cohort study. Use of
HT doubled the risk of incident surgically-confirmed
uterine fibroids in postmenopausal women at any BMI.
Adiposity alone had a lesser, but still significant effect,
with a 46 % increase in risk of fibroids in obese women
irrespective of history of HT use. When stratified by HT
use, increasing adiposity had a much stronger effect in
women who had never used HT, with a doubling of risk in
the obese group. The effect of BMI was also present in ever
users of HT, but they had much higher risks at any BMI,
and the additional effect of increased adiposity was
smaller.
Other groups have reported that uterine fibroid risk is
increased in overweight and obese women, although pub-
lished findings are inconsistent. The majority of studies
show an increasing risk with increasing BMI [11, 22–24]
but some have reported a J-shaped association [25–27], no
association [28–30], or even a decreased risk in obese
women [31]. Two other cohort studies, the Nurses’ Health
Study II [25] and the Black Women’s Health Study [27]
used surgically-defined cases, and both found strong as-
sociations between BMI and the risk of fibroids, which our
findings support.
There has been comparatively little published on the
effect of HT on uterine fibroid risk. Several small studies
with short-term follow-up have been published, and results
have been contradictory. For example, Yang et al. [32]
followed 37 early postmenopausal HT users and 35 mat-
ched controls who did not receive HT. All participants had
a solitary uterine fibroid at recruitment. Fibroids were
measured by transvaginal ultrasound at baseline and then
annually for 3 years. In the 3rd year there was a significant
increase in the fibroid volume in the HT group, but not in
the control group. The women treated with HT were also
significantly more likely to have an increase in fibroid
volume of[25 %, however numbers were small. A review
by Parker [10] which included Yang’s study, concluded
that despite being hormone-sensitive tumours, for the ma-
jority of postmenopausal women with fibroids hormone
therapy did not stimulate uterine or fibroid growth.
Two previous epidemiological studies that have exam-
ined the association between fibroids and HT use both re-
ported increased risks. In a retrospective case–control
study, Reed et al. [33] reported that use of combined oe-
strogen–progestagen HT was associated with an increased
risk of fibroids, although the excess risk was largely con-
fined to women who were not overweight (with BMI
\24 kg/m2). In the California Teachers Study [34] women
taking HT had a higher risk of surgically treated fibroids
than women who had never used HT. An increased risk
Table 2 Adjusteda relative risks of surgically-confirmed fibroids by menopausal hormone therapy (HT) use (ever vs. never)
HT use Number of women Number with fibroids Adjusted RR (95 % CI)
Never 402,970 1607 1.00 (Reference group)
Ever 207,634 1954 2.33 (2.18–2.49)
a Adjusted for smoking, oral contraceptive use, parity and deprivation, stratified by region
Table 3 Adjusteda relative
risks of surgically-confirmed
fibroids by body mass index
(BMI)
BMI Number of women Number with fibroids Adjusted RR (95 % CI)
\25 287,208 1508 1.00 (Reference group)
25–29.9 217,546 1273 1.15 (1.07–1.24)
30? 105,850 780 1.46 (1.33–1.59)
a Adjusted for smoking, oral contraceptive use, parity and deprivation, stratified by region
Table 4 Adjusteda relative
risks of surgically-confirmed
fibroids by hormone therapy use







Adjusted RR (95 % CI)
Never \25 182,870 576 1.00 (Reference group)
25–29.9 144,657 572 1.30 (1.16–1.46)
30? 75,443 459 2.00 (1.77–2.26)
Ever \25 103,338 932 2.78 (2.50–3.08)
25–29.9 72,889 701 3.05 (2.73–3.41)
30? 30,407 321 3.30 (2.86–3.79)
a Adjusted for smoking, oral contraceptive use, parity and deprivation, stratified by region
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was seen both in women who used oestrogens alone
(RR = 2.03, 95 % CI 1.17–3.52), and in those using
combined HT (RR = 2.38, 95 % CI 1.66–3.41), similar to
our overall findings.
Ovarian hormones are thought to play a key role in the
aetiology of fibroids. Early menarche and obesity increase
the incidence of fibroids, whereas high parity appears
protective [35]. Fibroids are hormone-sensitive tumours,
and so it is perhaps not surprising that use of HT doubles
incidence rates in postmenopausal women. Adiposity is
thought to affect the risk of fibroids in postmenopausal
women because peripheral tissues, principally body fat,
become the major source of circulating oestrogens (when
women are not taking HT) [36].
Our results suggest that fibroids do continue to be an issue
in postmenopausal women. Rates fall with age, and in
women 50–54, the only age groupwhich includes substantial
numbers of both premenopausal and postmenopausal
women, menopausal status affects incidence. At all ages,
uterine fibroids occur more frequently in postmenopausal
women who are obese, and those who use HT. Data in our
study were collected prospectively, and we limited our
analysis to women with a primary diagnosis of uterine fi-
broids during their hospital admission who also had a related
operative procedure. Our aim was to identify clinically sig-
nificant fibroids associated with a surgical intervention. A
limitation of our study is that we were not able to assess
whether having a raised BMI or using HT increased the risk
of developing new fibroids in the postmenopausal period, or
whether these factors decrease the likelihood of regression or
encourage growth of pre-existing fibroids.
What is the public health relevance of our findings?
Over half of the postmenopausal women with surgically-
confirmed fibroids in our cohort underwent a hysterectomy
or other major abdominal surgical procedure associated
with their disease. Approximately 50,000 hysterectomies
are performed annually in the UK [37]. At around £3282
per case [38], the 1810 hysterectomies in our study alone
would have cost the NHS about £6 million. The cost in
terms of quality of life, lost earnings, and morbidity to the
women may have been even greater. Surgically-confirmed
fibroids continue to occur in postmenopausal women,
especially those who are obese or using menopausal hor-
mone therapy. HT and BMI are potentially modifiable risk
factors for uterine fibroids in postmenopausal women.
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